Medtronic has received FDA approval for and is releasing its new second-generation FlexCath Advance Steerable Sheath for the Arctic Front Advance Cryoballoon System. The new delivery sheath features considerably greater flexing ability, offering physicians much greater control and ability to get to the left atrium in a speedy fashion.
The Arctic Front Advance is used to treat paroxysmal atrial fibrillation (PAF) by creating lesions around the pulmonary veins using a coolant and so isolating them.
The FlexCath Advance Steerable Sheath has a deflection of 135 degrees, compared to the 90 degree deflection rate of its first-generation predecessor. This greater degree of deflection may allow the cryoballoon to be better maneuvered and positioned within the heart to achieve maximum treatment benefit. The sheath includes the following features:
- Radiopaque marker band at 5 millimeters to provide enhanced visibility under fluoroscopy;
- Deflection mechanism with an ergonomic handle that optimizes the movement of the sheath; and
- Hemostasis valve that allows for introduction, withdrawal and exchanging of catheters and guidewires, while preventing air insertion and minimizing blood loss.
Product page: FlexCath Steerable Sheath…
Flashbacks: Medtronic Brings First Cryoballoon Ablation System for AFib to US; Medtronic Arctic Front Advance Cryoballoon for AFib Cleared in U.S., Europe; Medtronic’s Diagnostic Achieve Mapping Catheter Now Available in U.S.
Images courtesy of Medtronic.